Skip to main content

Efficacy of Nirmatrelvir/Ritonavir in High-Risk Adults with Preexisting SARS-CoV-2 Immunity: A Pooled Analysis of Two Randomized Controlled Trials

In brief

Nirmatrelvir/ritonavir cuts hospitalization or death from 1.9% to 0.5%

In a pooled analysis of 1,600 high-risk adults with prior vaccination or infection, hospitalization or death occurred in 0.5% taking nirmatrelvir/ritonavir versus 1.9% taking placebo. Treatment also shortened symptom recovery by two days, but these events were uncommon, and the analysis combined selected groups from two trials; the size of benefit in other immune populations remains uncertain.

Journal
Infectious diseases and therapy (Q1)
Published
12 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Heidi Leister-Tebbe, John M McLaughlin, Weihang Bao, Romina Quercia, Wayne Wisemandle, Jennifer Hammond
PMID
43020992
DOI
10.1007/s40121-026-01456-8

Why clinicians should know about it

Abstract

INTRODUCTION: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral treatment approved to treat mild-to-moderate COVID-19 among adults at high risk of severe disease. We conducted a pooled analysis of NMV/r efficacy among high-risk participants from two clinical trials who had evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity through vaccination or previous infection. METHODS: Data were pooled from a subset of participants from the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) trial (high-risk, unvaccinated) who were baseline seropositive for SARS-CoV-2 antibodies and high-risk Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) participants who were vaccinated against SARS-CoV-2. In both trials, participants were randomized within 5 days of symptom onset to twice-daily NMV/r 300/100 mg or placebo for 5 days. Endpoints included coronavirus disease 2019 (COVID-19)-related hospitalization or all-cause death through day 28, number of medical visits, time to symptom alleviation, and percentage of participants with severe symptoms. RESULTS: Overall, 1600 participants were included in the pooled analysis (NMV/r, 807 [EPIC-HR, n = 490; EPIC-SR, n = 317]; placebo, 793 [EPIC-HR, n = 479; EPIC-SR, n = 314]). NMV/r significantly reduced COVID-19-related hospitalization or all-cause death by 73.7% compared with placebo (0.5% versus 1.9%, P = 0.0104). Relative to placebo, NMV/r was also associated with fewer medical visits (21 versus 53, P = 0.0076) and a 2-day reduction in time to symptom alleviation (12 versus 14 days, P = 0.0470). Participants treated with NMV/r were less likely to report severe targeted COVID-19 symptoms compared with placebo (22.1% relative reduction on days 2-6 [P = 0.0441]; 46.6% relative reduction on days 7-28 [P = 0.0011]). CONCLUSIONS: NMV/r reduced hospitalization and death, medical visits, time to symptom alleviation, and severe symptoms among high-risk participants with preexisting SARS-CoV-2 immunity. CLINICAL TRIALS REGISTRATION: NCT04960202; NCT05011513.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.